Clinical trials: Neuroepithelial Tumor
Glioblastoma, IDH-Wildtype
Identifying Findings on Brain Scans That Could Help Make Better Predictions About Brain Cancer Progression, The GABLE Trial
This phase II trial studies whether different imaging techniques can provide additional and more accurate information than the usual approach for assessing the activity of tumors in patients with newly diagnosed glioblastoma.
- Trial name
- GABLE (NCT06319027)
- Testing
- Dynamic Susceptibility Contrast-Enhanced Magnetic Resonance Imaging, Fluciclovine F18, Gadolinium-Chelate
- Where
- 18 sites in United States
- Volunteers
- 100 people
- Sponsor
- ECOG-ACRIN Cancer Research Group
Glioblastoma
Efficacy and Safety of G-202 in PSMA-Positive Glioblastoma
Glioblastoma (GBM) comprises about 16% of all malignancies of the nervous system and over 50% of all gliomas. Standard of care for newly-diagnosed GBM is a combination of surgical debulking followed by concurrent radiotherapy and…
- Trial name
- NCT02876003
- Testing
- G-202
- Where
- United States
- Sponsor
- GenSpera, Inc.
Glioblastoma, Gliosarcoma
Temozolomide and Radiation Therapy With or Without Bevacizumab in Treating Patients With Newly Diagnosed Glioblastoma
This randomized phase III trial studies temozolomide (TMZ) and radiation therapy (RT) to compare how well they work with or without bevacizumab in treating patients with newly diagnosed glioblastoma or gliosarcoma.
- Conditions
- Glioblastoma, Gliosarcoma, Supratentorial Glioblastoma
- Trial name
- NCT00884741
- Testing
- 3-Dimensional Conformal Radiation Therapy, Bevacizumab, Intensity-Modulated Radiation Therapy
- Where
- 330 sites in United States, Canada and 1 more
- Volunteers
- 637 people
- Sponsor
- National Cancer Institute (NCI)
Brain Tumors, Central Nervous System Tumors
Low-Dose Radiation and Combination Chemotherapy Following Surgery in Children With Newly Diagnosed Medulloblastoma
RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells, but also damages normal cells in the developing brains of children.
- Conditions
- Brain Tumors, Central Nervous System Tumors, Medulloblastoma
- Trial name
- NCT00031590
- Testing
- Cisplatin, Cyclophosphamide, Etoposide
- Where
- 3 sites in United States
- Volunteers
- 30 people
- Sponsor
- Children's Hospital of Philadelphia
Glioblastoma
Personalized Radiation Therapy for GBM
The study is a pilot study to estimate the efficacy of personalized dose-escalation radiation therapy in patients with glioblastoma, as measured by estimating the median of progression-free survival.
- Trial name
- NCT03477513
- Testing
- Radation Therapy
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- Abramson Cancer Center at Penn Medicine
Glioma, Sarcoma
A Phase I Study of SU101 in Pediatric Patients With Refractory Malignancy
A dose escalation scale consisting of 5 dosage levels is being used to determine the maximum tolerated dose (MTD) of SU101. A minimum of 3 and a maximum of 6 patients will be enrolled at each dose level.
- Trial name
- NCT00001573
- Testing
- SU101
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- National Cancer Institute (NCI)
Glioma
Expanded Access Use of ONC201 in a Patient With Diffuse Intrinsic Pontine Gliomas
This is an intermediate-size expanded access protocol to provide ONC201 to patients with diffuse intrinsic pontine gliomas who cannot access ONC201 through clinical trials.
- Trial name
- NCT05392374
- Testing
- ONC201
- Where
- 10 sites in United States
- Sponsor
- Jazz Pharmaceuticals
Brain Tumor, Glioblastoma
Study of the Safety and Efficacy of Dichloroacetate (DCA) in Glioblastoma and Other Recurrent Brain Tumors
The purpose of this study is to evaluate the safety and tolerability of oral Dichloroacetate (DCA) in the treatment of recurrent malignant brain tumors (RMBTs).
- Trial name
- NCT01111097
- Testing
- Dichloroacetate
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- University of Florida
Glioblastoma, Anaplastic Astrocytoma
Super Selective Intra-arterial Repeated Infusion of Cetuximab (Erbitux) With Reirradiation for Treatment of Relapsed/Refractory GBM, AA, and AOA
Primary brain tumors are typically treated by surgery, radiation therapy and chemotherapy, either individually or in combination.
- Conditions
- Glioblastoma, Anaplastic Astrocytoma, Anaplastic Oligoastrocytoma, Glioma
- Trial name
- NCT02800486
- Testing
- Intra-arterial Cetuximab, Intra-arterial Mannitol, Hypofractionated re-irradiation
- Where
- United States
- Volunteers
- 37 people
- Sponsor
- Northwell Health
Glioblastoma (GBM)
Limited Target Volume Radiotherapy After Glioblastoma Surgery
Research on radiotherapy target volumes for glioblastoma is increasingly focused on exploring more limited yet effective irradiation fields, aiming to achieve local control while minimizing acute and long-term neurotoxicity.
- Trial name
- NCT07368283
- Testing
- limited-field radiotherapy
- Volunteers
- 79 people
- Sponsor
- Jiangxi Provincial Cancer Hospital
Glioma, Glioblastoma
Validation of Readiband™ Actigraph and Associated Sleep/Wake Classification Algorithms
This pilot study will assess feasibility and to obtain initial estimates of efficacy of Sleep Activity and Task Effectiveness (SAFTE) model, which can accurately estimate the impact of scheduling factors and sleep history on both…
- Trial name
- NCT03877861
- Testing
- Readiband Sleep Tracking
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- Allina Health System
Malignant Gliomas
Cetuximab, Bevacizumab and Irinotecan for Patients With Malignant Glioblastomas
Irinotecan has demonstrated activity in malignant gliomas in multiple phase II studies. The activity is limited, with an approximately 15 % response rate and a progression-free survival of 3-5 months.
- Trial name
- NCT00463073
- Testing
- Cetuximab, Bevacizumab, Irinotecan
- Where
- 3 sites in Denmark
- Volunteers
- 32 people
- Sponsor
- Copenhagen University Hospital, Rigshospitalet
Brain Tumor, Glioblastoma
Vaccination With Dendritic Cells Loaded With Brain Tumor Stem Cells for Progressive Malignant Brain Tumor
This is a single center Phase I study to determine the safety and maximum tolerated dose (MTD) of autologous dendritic cells (DCs) loaded with allogeneic brain tumor stem cells administered as a vaccination in children and adults…
- Conditions
- Brain Tumor, Glioblastoma, Medulloblastoma, Ependymoma
- Trial name
- NCT01171469
- Testing
- Dendritic Cells, Imiquimod
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
Brain and Central Nervous System Tumors
Imaging Procedure Using ALA in Finding Residual Tumor in Grade IV Malignant Astrocytoma
RATIONALE: Imaging procedures that use aminolevulinic acid (ALA) may help find and diagnose residual tumor in participants with grade IV malignant astrocytoma who are undergoing surgery to remove the tumor.
- Trial name
- NCT00752323
- Testing
- aminolevulinic acid, Surgical Resection
- Where
- United States
- Volunteers
- 73 people
- Sponsor
- Andrew Sloan, MD
Carcinoma, Midline
A Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of GSK525762 in Subjects With NUT Midline Carcinoma (NMC) and Other Cancers
This study is divided into two parts; Part 1 of the study is a dose escalation phase to select the recommended dose for Part 2 based on the safety, pharmacokinetic, and pharmacodynamic profiles observed after oral administration…
- Trial name
- NCT01587703
- Testing
- GSK525762
- Where
- 17 sites in United States, Australia and 5 more
- Volunteers
- 196 people
- Sponsor
- GlaxoSmithKline
Glioblastoma
Dendritic Cell Vaccination With Standard Postoperative Chemoradiation for the Treatment of Adult Glioblastoma
Effective treatments are desperately needed for glioblastoma (GBM) patients. This phase I clinical trial assesses the safety of a novel personalized dendritic-cell vaccine administered to GBM patients shortly after completing…
- Trial name
- NCT04552886
- Testing
- TH-1 Dendritic Cell Immunotherapy
- Where
- 2 sites in United States
- Volunteers
- 17 people
- Sponsor
- The Cooper Health System
Brain and Central Nervous System Tumors
Study of GDC-0084 in Pediatric Patients With Newly Diagnosed Diffuse Intrinsic Pontine Glioma or Diffuse Midline Gliomas
Pediatric high-grade gliomas are highly aggressive and treatment options are limited. The purpose of this first-in-pediatrics study is to examine the safety, tolerability, and pharmacokinetics of GDC-0084 and to estimate its…
- Trial name
- NCT03696355
- Testing
- GDC-0084, radiation therapy
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- St. Jude Children's Research Hospital
Glioma, Glioma, Malignant
Study of NUV-422 in Adults With Recurrent or Refractory High-grade Gliomas and Solid Tumors
At the time of study termination, NUV-422-02 was a first-in-human, open-label, Phase 1 dose escalation study designed to evaluate the safety and efficacy of NUV-422.
- Conditions
- Glioma, Glioma, Malignant, Glioma, Mixed, Glial Cell Tumors
- Trial name
- NCT04541225
- Testing
- NUV-422
- Where
- 12 sites in United States
- Volunteers
- 74 people
- Sponsor
- Nuvation Bio Inc.
Neuroblastoma
Local Control With Reduced-dose Radiotherapy for High-Risk Neuroblastoma
The purpose of this study is to give 12T a smaller dose of radiation in order to decrease these late side effects.
- Trial name
- NCT02245997
- Testing
- External beam radiotherapy, proton beam RT
- Where
- United States
- Volunteers
- 78 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Glioma of Brain
Glioma Microenvironment an Exploratory Study
Diffuse glioms are primary brain tumors characterized by infiltrative growth and high heterogeneity, which render the disease mostly incurable.
- Trial name
- NCT03189420
- Testing
- Tumor resection
- Where
- Brazil
- Volunteers
- 30 people
- Sponsor
- Hospital Sirio-Libanes
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.